Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof

Abstract

The present application relates to a method for the prevention or treatment of an abnormal cell proliferative disease in a mammal, wherein the method comprises administering to the mammal an effective amount of a 4′-thionucleoside compound or a pharmaceutically acceptable salt, ester, hydrate, solvate thereof, or racemate thereof, or a mixture thereof.

What is claimed is: 
     
         1 . A method for the prevention or treatment of an abnormal cell proliferative disease in a mammal, wherein the method comprises administering to the mammal an effective amount of a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, ester, hydrate, solvate thereof, or racemate thereof, or a mixture thereof. 
       
     
     
         2 . The method according to  claim 1 , wherein the abnormal cell proliferative disease is cancer and/or tumor and related disorders thereof. 
     
     
         3 . The method according to  claim 1 , wherein the effective amount of the compound is in a unit dose ranging from 0.1-1000 mg. 
     
     
         4 . The method according to  claim 3 , wherein the effective amount of the compound is in a unit dose ranging from 1-800 mg. 
     
     
         5 . The method according to  claim 4 , wherein the effective amount of the compound is in a unit dose ranging from 10-600 mg. 
     
     
         6 . The method according to  claim 5 , wherein the effective amount of the compound is in a unit dose ranging from 50-450 mg. 
     
     
         7 . The method according to  claim 6 , wherein the effective amount of the compound is in a unit dose ranging from 100-300 mg. 
     
     
         8 . The method according to  claim 1 , wherein an additional anti-tumour agent is administered. 
     
     
         9 . The method according to  claim 1 , wherein the effective amount is in a single dose unit or in multiple dose units. 
     
     
         10 . The method according to  claim 2 , wherein the cancer and/or tumor and related disorders thereof is selected from the group consisting of cancers in esophagus, stomach, intestine, rectum, mouth, pharynx, larynx, lung, colon, breast, uterus, endometrium, ovary, prostate, testis, bladder, kidney, liver, pancreas, bone, connective tissue, skin, eye, brain and central nervous system, as well as thyroid cancer, leukemia, Hodgkin disease, lymphoma and myeloma. 
     
     
         11 . The method according to  claim 1 , wherein the compound is administered at a dosage range of 0.1-1000 mg/kg body weight per day. 
     
     
         12 . The method according to  claim 11 , wherein the compound is administered at a dosage range of 1-800 mg/kg body weight per day. 
     
     
         13 . The method according to  claim 12 , wherein the compound is administered at a dosage range of 10-600 mg/kg body weight per day. 
     
     
         14 . The method according to  claim 13 , wherein the compound is administered at a dosage range of 100-400 mg/kg body weight per day. 
     
     
         15 . The method according to  claim 14 , wherein the compound is administered at a dosage range of 120-250 mg/kg body weight per day.